GlassScriptPhysician profile
Morgan Wong
NPI 1073900163
$5,899.67
in general payments reported to CMS, 2019-2025
20 companies · $1,984 in 2025
The $1,984 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,070 · 2022: $1,733 · 2023: $1,007 · 2024: $106 · 2025: $1,984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,296 · Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,295.98 |
| Food and Beverage | $801.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,499.57 | 2021-2025 | Overstitch Endoscopic Suturing System |
| Olympus Corporation of The Americas | $986.04 | 2021-2023 | Single Use Electrosurgical Knife Kd-655, Single Use Electrosurgical Hemostatic Forceps |
| Ovesco Endoscopy USA, INC. | $782.82 | 2025 | |
| Gilead Sciences, INC. | $341.41 | 2022-2025 | |
| 3-D Matrix, INC. | $321.29 | 2025 | |
| Medtronic, INC. | $230.93 | 2021-2022 | |
| Conmed Corporation | $142.58 | 2022 | |
| Apollo Endosurgery US INC | $103.05 | 2022 | |
| Endogastric Solutions, INC | $100.54 | 2021 | |
| Merit Medical Systems INC | $80.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.68 | 2022-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $39.84 | 2025 | Entyvio |
| Olympus America INC. | $39.74 | 2023-2024 | Endoclot Phs, Endoclot Sis |
| Abbvie INC. | $35.62 | 2024 | |
| Braintree Laboratories, INC. | $34.34 | 2024-2025 | Suflave, Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $33.15 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $30.32 | 2025 | Voquezna |
| Janssen Biotech, INC. | $22.36 | 2025 | Tremfya |
| Erbe USA INC | $20.00 | 2025 | Vio3, Apc3, Hapc |
| Micro-Tech Endoscopy USA, INC. | $11.82 | 2024 | Eyemx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.